Evidence map›Paper›PMID 37063290›Full record

ArticleFrontiers in pharmacology2023

Identification of novel immune-related molecular subtypes and a prognosis model to predict thyroid cancer prognosis and drug resistance.

Wei Zhang, Ting Liu, Xinyi Li, Tianshu Li, Xiangchi Ma, Dongxu Zhao, Yueyang Liu, Xueke Zheng, Xudong Zhao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A biomarker and molecular mechanism investigation for thyroid cancer.Central-European journal of immunology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Wei ZhangDepartment of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China.
Ting LiuDepartment of Otolaryngology-Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Xinyi LiDepartment of Otolaryngology-Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Tianshu LiDepartment of Otolaryngology-Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Xiangchi MaDepartment of Otolaryngology-Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Dongxu ZhaoDepartment of Otolaryngology-Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Yueyang LiuDepartment of Otolaryngology-Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Xueke ZhengDepartment of Otolaryngology-Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Xudong ZhaoDepartment of Otolaryngology-Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chemotherapy drugimmunemethylationmolecular subtypeprognosisthyroid cancer

Identifiers

PMID37063290
PMCPMC10098004
OpenAlexW4361276598

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.